Patents by Inventor Dean Stamos

Dean Stamos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted tetrahydrofurans as modulators of sodium channels
    Patent number: 11919887
    Abstract: Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.
    Type: Grant
    Filed: November 8, 2022
    Date of Patent: March 5, 2024
    Assignee: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Steven John Durrant, Nadia M. Ahmad, Elizabeth Mary Beck, Lidio Marx Carvalho Meireles, Ewa Iwona Chudyk, Gorka Etxebarria Jardi, Bhairavi Galan, Sara S. Hadida Ruah, Dennis James Hurley, Ronald Marcellus Knegtel, Timothy Donald Neubert, Joanne Louise Pinder, Joseph Pontillo, Robert Pullin, Yvonne Schmidt, David Matthew Shaw, Sarah Skerratt, Dean Stamos, Stephen Andrew Thomson, Anisa Nizarali Virani, Christopher Wray
  • Substituted tetrahydrofurans as modulators of sodium channels
    Patent number: 11834441
    Abstract: Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: December 5, 2023
    Assignee: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Steven John Durrant, Nadia Ahmad, Elizabeth Mary Beck, Lidio Marx Carvalho Meireles, Ewa Iwona Chudyk, Gorka Etxebarria Jardi, Bhairavi Galan, Sara S. Hadida Ruah, Dennis James Hurley, Ronald Marcellus Knegtel, Timothy Donald Neubert, Joanne Louise Pinder, Joseph Pontillo, Robert Pullin, Yvonne Schmidt, David Matthew Shaw, Sarah Skerratt, Dean Stamos, Stephen Andrew Thomson, Anisa Nizarali Virani, Christopher Wray
  • N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
    Patent number: 11827627
    Abstract: Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.
    Type: Grant
    Filed: June 3, 2022
    Date of Patent: November 28, 2023
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Elizabeth Mary Beck, Steven John Durrant, Sarah Skerratt, Robert Pullin, Gorka Etxebarria Jardi, David Matthew Shaw, Nadia M. Ahmad, Christopher Wray, Anisa Nizarali Virani, Kiri North, James Dodd, Michael Edward O'Donnell, Bhairavi Galan, Ronald Marcellus Knegtel, Ewa Iwona Chudyk, Joanne Louise Pinder, Stephen Andrew Thomson, Lidio Marx Carvalho Meireles, Dean Stamos, Yvonne Schmidt, Joseph Pontillo, Sara S. Hadida Ruah, Timothy Donald Neubert, Dennis James Hurley, Jinglan Zhou
  • Cereblon modulators and uses thereof
    Patent number: 11771689
    Abstract: Disclosed herein are compositions and methods for modulating cereblon neosubstrates. A small molecule modulator of Formula (I*), or a pharmaceutically acceptable salt or solvate thereof can be used to modulate cereblon neosubstrates.
    Type: Grant
    Filed: November 17, 2020
    Date of Patent: October 3, 2023
    Assignees: VIVIDION THERAPEUTICS, INC., THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Benjamin F. Cravatt, Matthew Patricelli, Dean Stamos, Gabe Simon, Benjamin Horning, David Weinstein, Ekaterina Vinogradova
  • SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS
    Publication number: 20230286961
    Abstract: Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.
    Type: Application
    Filed: November 8, 2022
    Publication date: September 14, 2023
    Inventors: Steven John Durrant, Nadia M. Ahmad, Elizabeth Mary Beck, Lidio Marx Carvalho Meireles, Ewa Iwona Chudyk, Gorka Etxebarria Jardi, Bhairavi Galan, Sara S. Hadida Ruah, Dennis James Hurley, Ronald Marcellus Knegtel, Timothy Donald Neubert, Joanne Louise Pinder, Joseph Pontillo, Robert Pullin, Yvonne Schmidt, David Matthew Shaw, Sarah Skerratt, Dean Stamos, Stephen Andrew Thomson, Anisa Nizarali Virani, Christopher Wray
  • IN VIVO ENGINEERED CEREBLON PROTEIN
    Publication number: 20220298213
    Abstract: Disclosed herein are in vivo engineered cereblon protein and methods of making the same. The in vivo engineered cereblon protein can include a site-specific non-naturally occurring modification at cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO: 2 or 3, the modification comprising a moiety resulting from an in vivo Michael addition reaction between an exogenous Michael acceptor and the cysteine 287 as set forth in SEQ ID NO: 1, or cysteine 286 as set forth in SEQ ID NO: 2 or 3.
    Type: Application
    Filed: May 23, 2022
    Publication date: September 22, 2022
    Inventors: David WEINSTEIN, Benjamin F. CRAVATT, Matthew PATRICELLI, Dean STAMOS, Gabe SIMON, Benjamin HORNING, Ekaterina VINOGRADOVA, Brian NORDIN, Kristen BALTGALVIS, Todd KINSELLA
  • CEREBLON MODULATORS AND USES THEREOF
    Publication number: 20220062248
    Abstract: Disclosed herein are compositions and methods for modulating cereblon neosubstrates. A small molecule modulator of Formula (I*), or a pharmaceutically acceptable salt or solvate thereof can be used to modulate cereblon neosubstrates.
    Type: Application
    Filed: November 17, 2020
    Publication date: March 3, 2022
    Inventors: Benjamin F. CRAVATT, Matthew PATRICELLI, Dean STAMOS, Gabe SIMON, Benjamin HORNING, David WEINSTEIN, Ekaterina VINOGRADOVA
  • IN VIVO ENGINEERED CEREBLON PROTEIN
    Publication number: 20210002337
    Abstract: Disclosed herein are in vivo engineered cereblon protein and methods of making the same. The in vivo engineered cereblon protein can include a site-specific non-naturally occurring modification at cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO: 2 or 3, the modification comprising a moiety resulting from an in vivo Michael addition reaction between an exogenous Michael acceptor and the cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO: 2 or 3.
    Type: Application
    Filed: June 16, 2020
    Publication date: January 7, 2021
    Inventors: David WEINSTEIN, Benjamin F. CRAVATT, Matthew PATRICELLI, Dean STAMOS, Gabe SIMON, Benjamin HORNING, Ekaterina VINOGRADOVA, Brian NORDIN, Kristen BALTGALVIS, Todd KINSELLA
  • Cereblon modulators and uses thereof
    Patent number: 10869860
    Abstract: Disclosed herein are compositions and methods for modulating cereblon neosubstrates. A small molecule modulator of Formula (I*), or a pharmaceutically acceptable salt or solvate thereof can be used to modulate cereblon neosubstrates.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: December 22, 2020
    Assignees: VIVIDION THERAPEUTICS, INC., THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Benjamin F. Cravatt, Matthew Patricelli, Dean Stamos, Gabe Simon, Benjamin Horning, David Weinstein, Ekaterina Vinogradova
  • In vivo engineered cereblon protein
    Patent number: 10781239
    Abstract: Disclosed herein are in vivo engineered cereblon protein and methods of making the same. The in vivo engineered cereblon protein can include a site-specific non-naturally occurring modification at cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO:2 or 3, the modification comprising a moiety resulting from an in vivo Michael addition reaction between an exogenous Michael acceptor and the cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO:2 or 3.
    Type: Grant
    Filed: August 8, 2019
    Date of Patent: September 22, 2020
    Assignees: VIVIDION THERAPEUTICS, INC., THE SCRIPPS RESEARCH INSTITUTE
    Inventors: David Weinstein, Benjamin F. Cravatt, Matthew Patricelli, Dean Stamos, Gabe Simon, Benjamin Horning, Ekaterina Vinogradova, Brian Nordin, Kristen Baltgalvis, Todd Kinsella
  • COMPOUNDS AND METHODS OF MODULATING PROTEIN DEGRADATION
    Publication number: 20200239530
    Abstract: Disclosed herein are protein-probe adducts and synthetic ligands that inhibit protein-probe adduct formation, in which the protein is part of the E3 ligase complex and the protein is modified to alter the substrate recognition of the E3 ligase complex. In some instances, also provided herein are protein-probe adducts and synthetic ligands that inhibit protein-probe adduct formation, in which the protein is modified or tagged for degradation. In some instances, additionally provided herein are cysteine-containing protein binding domains that interact with a probe and/or a ligand described herein.
    Type: Application
    Filed: September 27, 2018
    Publication date: July 30, 2020
    Inventors: Matthew PATRICELLI, Dean STAMOS, Gabe SIMON, Benjamin HORNING
  • IN VIVO ENGINEERED CEREBLON PROTEIN
    Publication number: 20200216507
    Abstract: Disclosed herein are in vivo engineered cereblon protein and methods of making the same. The in vivo engineered cereblon protein can include a site-specific non-naturally occurring modification at cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO: 2 or 3, the modification comprising a moiety resulting from an in vivo Michael addition reaction between an exogenous Michael acceptor and the cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO: 2 or 3.
    Type: Application
    Filed: August 8, 2019
    Publication date: July 9, 2020
    Inventors: David WEINSTEIN, Benjamin F. CRAVATT, Matthew PATRICELLI, Dean STAMOS, Gabe SIMON, Benjamin HORNING
  • CEREBLON MODULATORS AND USES THEREOF
    Publication number: 20200206201
    Abstract: Disclosed herein are compositions and methods for modulating cereblon neosubstrates. A small molecule modulator of Formula (I*), or a pharmaceutically acceptable salt or solvate thereof can be used to modulate cereblon neosubstrates.
    Type: Application
    Filed: July 3, 2019
    Publication date: July 2, 2020
    Inventors: Benjamin F. CRAVATT, Matthew PATRICELLI, Dean STAMOS, Gabe SIMON, Benjamin HORNING, David WEINSTEIN
  • Pyrrolidinone benzenesulfonamide derivatives as modulators of ion channels
    Patent number: 8841282
    Abstract: The present invention relates to pyrrolidinone benzenesulfonamides of the following formula: useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders, such as pain.
    Type: Grant
    Filed: August 15, 2013
    Date of Patent: September 23, 2014
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Dean Stamos, Esther Ann Martinborough, Nicole Hilgraf, Timothy Donald Neubert, Mehdi Numa, Tara Whitney, Aarti Sameer Kawatkar
  • Pyrrolidinone Benzenesulfonamide Derivatives as Modulators of Ion Channels
    Publication number: 20130338119
    Abstract: The present invention relates to heterocyclic derivatives useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
    Type: Application
    Filed: August 15, 2013
    Publication date: December 19, 2013
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Dean Stamos, Esther Ann Martinborough, Nicole Hilgraf, Timothy Donald Neubert, Mehdi Numa, Tara Whitney, Aarti Sameer Kawatkar
  • Piperidine and piperazine phenyl sulfonamides as modulators of ion channels
    Patent number: 8586589
    Abstract: The present invention relates to piperidine and piperazine phenyl sulfonamides useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders, including for example the treatment of pain.
    Type: Grant
    Filed: October 2, 2012
    Date of Patent: November 19, 2013
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Esther Martinborough, Lev T. D. Fanning, Urvi Sheth, Dean Wilson, Andreas P. Termin, Timothy D. Neubert, Nicole Hilgraf, Tara Leanne Hampton, Tara Whitney, Aarti Sameer Kawatkar, Danielle Lehsten, Dean Stamos, Jinglan Zhou, Vijayalaksmi Arumugam, Corey Anderson
  • Heterocyclic inhibitors of c-Met and uses thereof
    Patent number: 8481538
    Abstract: The present invention provides compounds useful as inhibitors of c-Met tyrosine kinase. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various proliferative disorders.
    Type: Grant
    Filed: September 18, 2007
    Date of Patent: July 9, 2013
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Alexander Aronov, Jon Come, John Court, David Deininger, David Lauffer, Pan Li, Kira McGinty, Suganthini Nanthakumar, Dean Stamos, Kirk Tanner
  • Gyrase inhibitors and uses thereof
    Patent number: 8426426
    Abstract: The present invention relates to compounds which inhibit bacterial gyrase and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention also relates to methods for treating bacterial infections in mammals. The present invention also relates to a method for preparing these compounds.
    Type: Grant
    Filed: April 16, 2010
    Date of Patent: April 23, 2013
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Paul Charifson, David Deininger, Joseph Drumm, Anne-Laure Grillot, Yusheng Liao, Patricia Oliver-Shaffer, Dean Stamos
  • Gyrase inhibitors and uses thereof
    Patent number: 8404852
    Abstract: The present invention relates to methods of treating, preventing, or lessening the severity of resistant bacterial infections in mammals, utilizing compounds of formula I or formula VII or pharmaceutically salts thereof. The present invention also relates to methods of using compounds of formula I or formula VII in combination with one or more additional antibacterial agents and/or one or more additional therapeutic agents that increase the susceptibility of bacterial organisms to antibiotics.
    Type: Grant
    Filed: September 16, 2011
    Date of Patent: March 26, 2013
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Paul S. Charifson, David D. Deininger, Anne-Laure Grillot, Yusheng Liao, Steven M. Ronkin, Dean Stamos, Emanuele Perola, Tiansheng Wang, Arnaud Le Tiran, Joseph Drumm
  • Gyrase inhibitors and uses thereof
    Patent number: 8394803
    Abstract: The present invention relates to compounds of formula I: or a pharmaceutically acceptable salt thereof, that inhibit bacterial gyrase and/or Topo IV and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention also relates to methods for treating bacterial infections in mammals.
    Type: Grant
    Filed: November 6, 2006
    Date of Patent: March 12, 2013
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Paul Charifson, David Deininger, Joseph Drumm, Anne-Laure Grillot, Arnaud LeTiran, Yusheng Liao, Emanuele Perola, Steven Ronkin, Dean Stamos, Tiansheng Wang